Physician profile
Deborah Spey
NPI 1417975640
$6,792.91
in general payments reported to CMS, 2019-2025
28 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $435 · 2021: $1,026 · 2022: $1,272 · 2023: $1,096 · 2024: $702 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,910.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,817.80 | 2019-2022 | |
| Abbvie INC. | $1,531.11 | 2020-2025 | Rinvoq, Skyrizi |
| Incyte Corporation | $440.50 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $406.53 | 2020-2025 | Odomzo, Blu-U, Ilumya |
| Lilly USA, LLC | $374.48 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $245.60 | 2019-2025 | Cabtreo, Duobrii, Arazlo |
| Pfizer INC. | $227.25 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $209.98 | 2021-2025 | Dupixent |
| Genzyme Corporation | $197.80 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $195.24 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $152.32 | 2020-2024 | |
| Leo Pharma INC. | $138.21 | 2021-2025 | Adbry, Anzupgo |
| Revance Therapeutics, INC. | $119.23 | 2024-2025 | Daxxify |
| Amgen INC. | $116.77 | 2020-2023 | Otezla |
| Galderma Laboratories, L.P. | $109.05 | 2020-2023 | Oracea, Epsolay, Aklief |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $89.31 | 2020-2023 | |
| Almirall LLC | $87.30 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $62.81 | 2023-2025 | Sotyktu |
| Fidia Pharma USA INC. | $52.90 | 2024-2025 | |
| Janssen Biotech, INC. | $50.68 | 2021-2025 | Tremfya, Simponi, Stelara |
| Ucb, INC. | $42.51 | 2020-2025 | Bimzelx |
| Botanix Sb INC | $36.43 | 2025 | Sofdra |
| Organon LLC | $17.47 | 2025 | Hadlima |
| Sandoz INC. | $16.58 | 2020 | |
| Dermira, INC. | $14.58 | 2020 | |
| Epi Health, LLC | $14.58 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.21 | 2023 | Spevigo |
| Biofrontera INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Spey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.